Prescription Opioid Abusers Prefer to Get High on Oxycodone and Hydrocodone
Philadelphia, PA, December 2, 2013
Researchers investigate factors that influence the choice of abused
drugs, reports PAIN®
Researchers investigate factors that influence the choice of abused drugs, reports PAIN®
opioid abuse has reached epidemic levels in the past 15 years. Scientists investigating
why people favor one drug over another have found that oxycodone and
hydrocodone are the drugs of choice for 75% of opioid-dependent individuals.
Their results, published in the current issue of PAIN®,show that oxycodone was the
most popular drug overall because of the quality of the high for those who
sought such effects. Nonetheless, hydrocodone remains one of the most popular
primary drugs, even though it has lower euphoric qualities. In addition, users
say they are concerned about acetaminophen poisoning since, until recently, all
hydrocodone products contained non-steroidal anti-inflammatory drugs.
Opioids used to manage pain in general medicine and dentistry are not only well known for their analgesic properties, but also for their ability to produce a high. Although most opioid classes have seen increases in their misuse, hydrocodone and oxycodone, which are the most commonly prescribed opioids in the United States, are by far the most popular drugs of choice among prescription opioid abusers. Both drugs have a long history of use for nontherapeutic purposes.
Investigators from the Department of Psychiatry at Washington University in St. Louis (Missouri) and the Center for Applied Research on Substance Use and Health Disparities at Nova Southeastern University in Miami, Fla., sought to identify the factors that influence the choice of primary drugs of abuse in 3,520 opioid-dependent individuals entering drug-treatment programs across the United States. Prospective participants were identified through the ongoing nationwide Survey of Key Informants' Patients (SKIP) program. That program is a key element of the post marketing surveillance system, Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System. SKIP consists of more than 150 treatment centers, both public and privately funded, and is geographically balanced with urban, suburban, and rural patients.
To help determine the choice of one opioid over another, researchers used anonymous, self-administered surveys to assess the influence of sex, age, race/ethnicity, area of residence, source of income, health-care coverage, drug-use patterns, and other decision-related factors.
To add richness to the study, investigators also recruited 200 patients who previously had completed the SKIP survey and indicated that they were willing to give up their anonymity to participate in a follow-up study using non-structured, qualitative interviews, dubbed Researchers and Participants Interacting Directly (RAPID).
Oxycodone was the choice of significantly more users (44.7%) than hydrocodone (29.4%) because the quality of the high was viewed to be much better by oxycodone users (54%) than hydrocodone users (20%). Far fewer participants selected any other opioid as their primary drug. While 90% of users selected mood alteration as a reason for using their primary drug, a very large percentage of each sample – 50% to 60% -- indicated that the treatment of pain was also a factor in their use. This finding suggests that, in the view of many patients, pain was inadequately managed.
Despite its high abuse rates among prescription opioid abusers, hydrocodone is viewed as less attractive than oxycodone by active abusers because, unlike many oxycodone products that are 100% oxycodone, hydrocodone is frequently combined with acetaminophen. This can deter users from increasing the dose in order to get high.
Oxycodone users are more likely to tamper with their drugs in order to inhale or inject the drug. The introduction of an OxyContin abuse-deterrent formulation in 2010 led to a significant drop in the use of OxyContin, but the overall impact on total oxycodone users was not sufficiently significant to change the rank of order of abuse rates; oxycodone products remained more popular than hydrocodone products.
A key question the researchers set out to answer is why hydrocodone remains one of the most popular primary drugs even though it produces a lower quality of high and raises the potential for acetaminophen poisoning.
"The data show that hydrocodone is popular because it is relatively inexpensive, easily accessible through physicians, friends, and families, and is perceived as relatively safe to use, particularly by risk-averse users. This group includes generally risk-averse women, elderly people, non-injectors, and those who prefer safer modes of acquisition than dealers, such as doctors, friends, or family members," says Theodore J. Cicero, PhD, of the Department of Psychiatry at Washington University in St. Louis. "In contrast, we found that oxycodone is much more attractive to risk-tolerant young male users who prefer to inject or snort their drugs to get high and are willing to use riskier forms of diversion despite paying twice as much for oxycodone than hydrocodone.
"It is clear that not all drug abusers share the same characteristics," he continues. "The decision to use one drug over another is a complex one, largely attributable to individual differences such as personality, gender, age, and other factors. Prevention and treatment approaches should benefit from this because it may help prescribing physicians determine which drug to prescribe and monitor for abuse."
# # #
Notes for editors
"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States," by Theodore J. Cicero, PhD; Matthew S. Ellis, MPE; Hilary L. Surratt, PhD; Steven P. Kurtz, PhD (DOI: http://dx.doi.org/10.1016/j.pain.2013.07.025). It appears in PAIN, Volume 154, Issue 12 (December 2013) published by Elsevier.
Full text of the article is available to credentialed journalists upon request. Contact Terry Materese at +1 215 239 3196 or firstname.lastname@example.org for copies. Journalists wishing to interview the authors should contact James Dryden at the Office of Medical Public Affairs for Washington University in St. Louis at +1 314 286 0110 or email@example.com.
PAIN®, the official journal of the International Association for the Study of Pain® (IASP®), publishes 12 issues per year of original research on the nature, mechanisms, and treatment of pain. This peer-reviewed journal provides a forum for the dissemination of research in the basic and clinical sciences of multidisciplinary interest and is cited in Current Contents and MEDLINE. It continues to be ranked No.1 out of the 29 journals in the Anesthesiology category, according to the2012 Journal Citation Reports, published by Thomson Reuters. www.painjournalonline.com
About the International Association For The Study of PAIN® (IASP®)
IASP® is the world's largest multidisciplinary organization focused specifically on pain research and treatment. It is the leading professional forum for science, practice, and education in the field of pain, bringing together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain and to translate that knowledge into improved pain relief worldwide. Founded in 1973, IASP has nearly 8,000 members from 133 countries and in 90 chapters. www.iasp-pain.org
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 215 239 3196
+1 215 327 9934